The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Belantamab mafodotin in myeloma: advantages and disadvantages
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the mode of action of the BCMA-targeting antibody-drug conjugate (ADC) belantamab mafodotin (belamaf) in patients with relapsed/refractory multiple myeloma. The DREAMM-2 study (NCT03525678) has shown good overall response rates, but its use was associated with notable adverse events, including thrombocytopenia and corneal defects. Dr Popat goes on to highlight that with ophthalmology collaboration, belamaf can be managed effectively and will be added to standard of care regimens in the near future. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Honoraria: Takeda, Abbvie, GSK
Consultancy: BMS, Janssen, GSK
